x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DIA-0243092
| Product Information | |
|---|---|
| CAS No. | 1298086-22-2 |
| Synonyms | PF-04971729-d5 |
| Formula | C22H20D5ClO7 |
| Molecular Weight | 441.91 |
| SMILES | O[C@H]1[C@]2(C3=CC(CC4=CC=C(C=C4)OC([2H])([2H])C([2H])([2H])[2H])=C(C=C3)Cl)O[C@@](CO2)([C@H]([C@@H]1O)O)CO |
| Target | SGLT |
| Product Description | Ertugliflozin-d5 is the deuterium labeled Ertugliflozin. Ertugliflozin (PF-04971729) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC50 of 0.877 nM for h-SGLT2. Has the potential for the treatment of type 2 diabetes mellitus. |
| Format & Storage | |
|---|---|
| Shipping | Room temperature in the continental U.S. Other areas may vary. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
